170 related articles for article (PubMed ID: 25026301)
1. High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients.
Cañadas I; Taus A; González I; Villanueva X; Gimeno J; Pijuan L; Dómine M; Sánchez-Font A; Vollmer I; Menéndez S; Arpí O; Mojal S; Rojo F; Rovira A; Albanell J; Arriola E
Oncotarget; 2014 Jul; 5(14):5246-56. PubMed ID: 25026301
[TBL] [Abstract][Full Text] [Related]
2. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
Cañadas I; Rojo F; Taus Á; Arpí O; Arumí-Uría M; Pijuan L; Menéndez S; Zazo S; Dómine M; Salido M; Mojal S; García de Herreros A; Rovira A; Albanell J; Arriola E
Clin Cancer Res; 2014 Feb; 20(4):938-50. PubMed ID: 24284055
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal-Epithelial Transition and Circulating Tumor Cells in Small Cell Lung Cancer.
Hamilton G; Rath B
Adv Exp Med Biol; 2017; 994():229-245. PubMed ID: 28560677
[TBL] [Abstract][Full Text] [Related]
4. Cancer Stem Cells, Epithelial to Mesenchymal Markers, and Circulating Tumor Cells in Small Cell Lung Cancer.
Pore M; Meijer C; de Bock GH; Boersma-van Ek W; Terstappen LW; Groen HJ; Timens W; Kruyt FA; Hiltermann TJ
Clin Lung Cancer; 2016 Nov; 17(6):535-542. PubMed ID: 27363902
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer.
Tsuji T; Sakamori Y; Ozasa H; Yagi Y; Ajimizu H; Yasuda Y; Funazo T; Nomizo T; Yoshida H; Nagai H; Maeno K; Oguri T; Hirai T; Kim YH
Oncotarget; 2017 Sep; 8(42):71805-71816. PubMed ID: 29069748
[TBL] [Abstract][Full Text] [Related]
6. Small cell lung cancer: Circulating tumor cells of extended stage patients express a mesenchymal-epithelial transition phenotype.
Hamilton G; Hochmair M; Rath B; Klameth L; Zeillinger R
Cell Adh Migr; 2016 Jul; 10(4):360-7. PubMed ID: 26919626
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer.
Klotz DM; Link T; Wimberger P; Kuhlmann JD
Mol Oncol; 2021 Dec; 15(12):3626-3638. PubMed ID: 33738970
[TBL] [Abstract][Full Text] [Related]
8. Detection of serum protein and circulating mRNA of cMET, HGF EGF and EGFR levels in lung cancer patients to guide individualized therapy.
Serilmez M; Özgür E; Karaman S; Gezer U; Duranyıldız D
Cancer Biomark; 2019; 25(2):177-184. PubMed ID: 31104010
[TBL] [Abstract][Full Text] [Related]
9. Soluble hepatocyte growth factor (sHGF) and vascular endothelial growth factor (sVEGF) in adult acute myeloid leukemia: relationship to disease characteristics.
Aref S; Mabed M; Sakrana M; Goda T; El-Sherbiny M
Hematology; 2002 Oct; 7(5):273-9. PubMed ID: 12850814
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive value of plasma D-dimer levels in patients with small-cell lung cancer.
Zhang C; Jia Y; Jia Y; Zhang X; Li K
Int J Clin Oncol; 2018 Dec; 23(6):1070-1075. PubMed ID: 30168089
[TBL] [Abstract][Full Text] [Related]
11. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
[TBL] [Abstract][Full Text] [Related]
12. Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1.
Ito T; Kudoh S; Ichimura T; Fujino K; Hassan WA; Udaka N
Hum Cell; 2017 Jan; 30(1):1-10. PubMed ID: 27785690
[TBL] [Abstract][Full Text] [Related]
13. Tumor cell heterogeneity in Small Cell Lung Cancer (SCLC): phenotypical and functional differences associated with Epithelial-Mesenchymal Transition (EMT) and DNA methylation changes.
Krohn A; Ahrens T; Yalcin A; Plönes T; Wehrle J; Taromi S; Wollner S; Follo M; Brabletz T; Mani SA; Claus R; Hackanson B; Burger M
PLoS One; 2014; 9(6):e100249. PubMed ID: 24959847
[TBL] [Abstract][Full Text] [Related]
14. Serum YKL-40 level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer.
Xu CH; Yu LK; Hao KK
PLoS One; 2014; 9(5):e96384. PubMed ID: 24801872
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer.
Messaritakis I; Politaki E; Kotsakis A; Dermitzaki EK; Koinis F; Lagoudaki E; Koutsopoulos A; Kallergi G; Souglakos J; Georgoulias V
PLoS One; 2017; 12(7):e0181211. PubMed ID: 28719656
[TBL] [Abstract][Full Text] [Related]
16. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
17. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.
Taniguchi H; Yamada T; Takeuchi S; Arai S; Fukuda K; Sakamoto S; Kawada M; Yamaguchi H; Mukae H; Yano S
Cancer Sci; 2017 Jul; 108(7):1378-1385. PubMed ID: 28474864
[TBL] [Abstract][Full Text] [Related]
18. MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines.
Arriola E; Cañadas I; Arumí-Uría M; Dómine M; Lopez-Vilariño JA; Arpí O; Salido M; Menéndez S; Grande E; Hirsch FR; Serrano S; Bellosillo B; Rojo F; Rovira A; Albanell J
Br J Cancer; 2011 Sep; 105(6):814-23. PubMed ID: 21847116
[TBL] [Abstract][Full Text] [Related]
19. DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer.
Huang J; Cao D; Sha J; Zhu X; Han S
Biochem Biophys Res Commun; 2019 Jun; 514(3):853-860. PubMed ID: 31079917
[TBL] [Abstract][Full Text] [Related]
20. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
